31 March 2012
Kidney transplantation in Mongolia using effective and economical immunosuppression – a three-year experience
B. Tumurbaatar, D. Nyamsuren, D. Bayan-Undur, L. Jambaljav, B. Byambadash, J. Sarantsetseg, L. GanboldDOI: 10.12659/AOT.882647
Ann Transplant 2012; 17(1): 132-139
Abstract
Between August 2006 and August 2009, 34 ethnic Mongolians were the recipients of a kidney transplant at the Central Clinical Hospital in Ulaanbaatar, Mongolia. In 31 of the operations the donor was either a sibling or parent. In 4 recipients the donors were 2 recently deceased accident victims following controlled cardiac arrest and after next of kin permission. All 4 recipients are alive with life-supporting function. Appropriate legislation was passed in 2008. Thirty-one of the 34 recipients (91%) are alive. The 1-year patient and graft survival is 91% and 82%, respectively. In all cases, recipients received 1 dose of Campath 1 preoperatively followed by monotherapy with either Cyclosporin or Tacrolimus. Due to the remote geographical location of some of the recipients, appropriate serum drug levels were difficult to monitor. Azathioprine was therefore added in the last 13 recipients. Except for acute rejection episodes, no patients received steroid therapy. There were 7 diagnosed and treated acute rejections in the 34 recipients (21%). The mean annual cost of the immunosuppressive therapy period compared favorably with neighboring China and with costs in Spain. We conclude that the use of Campath 1 together with a non-steroid maintenance immunosuppressive regimen provides both economical and acceptable graft and patient survival in a developing country.
Keywords: Kidney Transplantation in Mongolia, Economical Immunosuppression, Legislation, Use Of Deceased Donors
In Press
08 Mar 2024 : Original article
Association of Coronary Calcium Score on Cardiac PET During Pre-Kidney Transplant Assessment with Persisten...Ann Transplant In Press; DOI: 10.12659/AOT.943532
14 Mar 2024 : Original article
Impact of Blood Products Transfusion on Patients in the Immediate Post-Lung Transplant Period: A Cohort StudyAnn Transplant In Press; DOI: 10.12659/AOT.943652
14 Mar 2024 : Case report
Treatment of Cavernous Transformation of Portal Vein Caused by Hepatic Cystic Echinococcosis Using Ex Vivo ...Ann Transplant In Press; DOI: 10.12659/AOT.942358
15 Mar 2024 : Review article
Approaches and Challenges in the Current Management of Cytomegalovirus in Transplant Recipients: Highlighti...Ann Transplant In Press; DOI: 10.12659/AOT.941185
Most Viewed Current Articles
05 Apr 2022 : Original article
Impact of Statins on Hepatocellular Carcinoma Recurrence After Living-Donor Liver TransplantationDOI :10.12659/AOT.935604
Ann Transplant 2022; 27:e935604
12 Jan 2022 : Original article
Risk Factors for Developing BK Virus-Associated Nephropathy: A Single-Center Retrospective Cohort Study of ...DOI :10.12659/AOT.934738
Ann Transplant 2022; 27:e934738
22 Nov 2022 : Original article
Long-Term Effects of Everolimus-Facilitated Tacrolimus Reduction in Living-Donor Liver Transplant Recipient...DOI :10.12659/AOT.937988
Ann Transplant 2022; 27:e937988
15 Mar 2022 : Case report
Combined Liver, Pancreas-Duodenum, and Kidney Transplantation for Patients with Hepatitis B Cirrhosis, Urem...DOI :10.12659/AOT.935860
Ann Transplant 2022; 27:e935860